Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study.

BioPharma Dive staff Member since June 5, 2024

Loading + Follow Following